MDACC Study No:2013-0160 ( NCT No: NCT01882946)
Title:A Phase I/II clinical trial evaluating DCVax-Direct, autologous activated dendritic cells for intratumoral injection, in patients with solid tumors
Principal Investigator:Vivek Subbiah
Treatment Agent:Dendritic Cells
Study Status:Open
Study Description:The goal of Phase I of this clinical research study is to find the highest
tolerable dose
of DCVax-Direct that can be given to patients with a locally advanced or
metastatic solid tumor cancer.

The goal of Phase II of this study is to learn about the safety of DCVax-Direct
learn if it can help to control the disease by causing an immune response
against the
cancer cells. Another goal of this part of the study is to learn if
DCVax-Direct causes any changes to the tumor.

This is the first study using DCVax-Direct in humans.
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I/Phase II
Treatment Agents:Dendritic Cells
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Northwest Biotherapeutics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Vivek Subbiah
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults